 |
21 Diseases |  |
0 Trials |
|
0 Trials |  |
4 News |  |
- | GSK356278 / GSK
Journal: Quantification of human brain PDE4 occupancy by GSK356278: A [(11)C](R)-rolipram PET study. (Pubmed Central) - Aug 15, 2019
We present the first report of a direct estimation of PDE4 blockade in the living human brain. In vivo affinity of GSK356278 for the PDE4, estimated in this early phase study, was combined with GSK356278 safety and tolerability data to decide on a therapeutic dose for future clinical development.
- GSK356278 / GSK
New P1 trial: Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease (clinicaltrials.gov) - May 17, 2012
P1, N=8, Completed, Sponsor: GlaxoSmithKline
- | GSK356278 / GSK
Trial completion: A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 (clinicaltrials.gov) - Apr 18, 2012
P1, N=36, Completed, Sponsor: GlaxoSmithKline
In vivo affinity of GSK356278 for the PDE4, estimated in this early phase study, was combined with GSK356278 safety and tolerability data to decide on a therapeutic dose for future clinical development. Recruiting --> Completed
- | GSK356278 / GSK
New P1 trial: A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278 (clinicaltrials.gov) - Apr 8, 2012
P1, N=36, Completed, Sponsor: GlaxoSmithKline